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Abstract 
Notwithstanding tremendous research efforts, the cause of Alzheimer’s disease (AD) remains elusive and 
there is no curative treatment. The cholinergic hypothesis presented 35 years ago was the first major 
evidence-based hypothesis regarding AD etiology. It proposed that the depletion of brain acetylcholine 
was a primary cause of cognitive decline in advanced age and AD. It relied on a series of observations 
obtained in aged animals, elderly and AD patients which pointed to dysfunctions of cholinergic basal 
forebrain, similarities between cognitive impairments induced by anticholinergic drugs and those found 
in advanced age and AD, and beneficial effects of drugs stimulating cholinergic activity. This review 
comes back on these major results to show how this hypothesis provided the drive for the development 
of anticholinesterase inhibitor-based therapies of AD, the almost exclusive approved treatment in use 
despite transient and modest efficacy. New ideas for improving cholinergic therapies are also compared 
and discussed in light of the current revival of the cholinergic hypothesis based on two sets of evidence 
from new animal models and refined imagery techniques in humans. First, human and animal studies 
agree on detecting signs of cholinergic dysfunctions much earlier than initially thought. Second, 
alterations of the cholinergic system are deeply intertwined with its reactive responses providing the 
brain with efficient compensatory mechanisms to delay the conversion to AD. Active research in this field 
should give new insight to develop multi-therapies incorporating cholinergic manipulation, as well as 
early biomarkers of AD allowing earlier diagnostics. This is of prime importance to counteract a disease 
that is now recognized to start early in adult life. 
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1. Introduction 
The etiology and early pathogenesis of Alzheimer’s disease (AD) in its major sporadic form still remains 
highly mysterious mainly because causative pathways are very likely multifactorial. The greater known 
risk factor in the development of AD is aging and the major genetic risk factor is the apolipoprotein E 
gene allele APOE4. The most prominent clinical sign of AD is memory loss. Several forms of memory are 
affected at the early stage like episodic memory and working memory, both characterized by difficulties 
to recall information gathered during specific events (Almkvist, 1996; Salmon, 2011). Early deficits in 
spatial navigation tasks have also been reported (Kalová et al., 2005; Hort et al., 2007). As these forms of 
memory are also affected in normal aging (Moffat, 2009; Gazova et al., 2013), although to a much lesser 
extent, the frontiers between normal and pathological cognitive decline are difficult to set at the earliest 
stages of the disease. As the pathology progresses, the worsening of these deficits generates increasing 
perturbations of everyday life and compromises the quality of life of patients and their immediate 
entourage. Further aggravation of the pattern of cognitive deficits and emergence of other behavioral 
disturbance most often require institutional care, creating affective and financial burdens on families and 
heavy costs for the society. At the neuropathological level, brains of AD patients are expected to show 
the two main hallmarks of the disease, namely senile plaques and neurofibrillary tangles. Senile plaques 
are primarily constituted of the β-amyloid peptide (Aβ) which accumulates in the brain due to abnormal 
regulation of amyloidogenic proteolysis of the β-amyloid precursor protein (APP) and altered clearance 
of Aβ. Rare forms of early onset familial AD (FAD) are mainly due to gene mutations affecting APP 
metabolism in favor of Aβ accumulation. Neurofibrillary tangles are largely formed of abnormally 
phosphorylated tau protein. Among a constellation of other neuropathological signs, there is also a 
marked brain inflammatory reaction and a relatively specific pattern of cell loss which affects primarily 
the temporal lobe and the cholinergic basal forebrain. The present review focuses on the cholinergic 
alterations associated with AD and the development of the cholinergic hypothesis which prompted the 
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use of cholinomimetic drugs as the first therapeutic approach to AD. Our aim is to enlighten how 
complementary animal and human studies can be at each step of the development of cholinergic drug in 
the past and the future. 
 
2. AD and the cholinergic hypothesis  
2.1 The cholinergic system 
Acetylcholine (ACh) is a neurotransmitter released by neurons from the peripheral and central nervous 
systems. The central cholinergic system is mainly organized in six nuclei (Ch1 to Ch6) which differ by their 
anatomical localization, functional characteristics and patterns of projection (Mesulam et al., 1983). Four 
of them form the basal forebrain cholinergic system: the medial septum (MS; Ch1), the diagonal band of 
Broca (Ch2, Ch3) and the nucleus basalis of Meynert (NBM; nucleus basalis magnocellularis in rodents; 
Ch4). Ch5 and Ch6 cholinergic neurons are located in the brain stem within the pedoculopontine nucleus 
and laterodorsal tegmental nucleus, respectively. A third main source of central ACh is provided by local 
projections of striatal cholinergic interneurons, but  these cholinergic neurons, like those of ch5-6, are 
relatively preserved by AD (Jellinger, 1988; Geula et al., 1990). In contrast, the basal forebrain cholinergic 
system appears as the main locus of cholinergic dysfunctions associated with AD, as developed below. 
Cholinergic neurons of the MS (Ch1) and vertical limb of the diagonal band of Broca (Ch2) provide the 
main supply of ACh to the hippocampus and the entorhinal cortex, whereas those of the nucleus basalis 
of Meynert mainly innervate the cerebral cortex and the amygdala (Mesulam et al., 1992; Kitt et al., 
1994).  
ACh is synthesized by the choline acetyl transferase (ChAT) from two immediate precursors, choline and 
acetyl-coenzyme A. It is then packed by the vesicular acetylcholine transporter inside presynaptic 
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vesicles of axonal terminals. Once released by the presynaptic cholinergic neurons, ACh binds to 
cholinergic receptors present on post-synaptic or pre-synaptic cell membranes. It is subsequently 
hydrolyzed in choline and acetate by the acethylcholinesterase enzyme (AChE) or by the less specific 
butyrylcholinesterase enzyme (BuChE) (Unzeta et al., 2016). Both are found in neuronal synapses, 
though at a much higher concentration for AChE. BuChE is also less selective for ACh and operates with 
different kinetics. These enzymes have two substrate binding sites: the catalytic anionic site responsible 
for the hydrolysis itself and the peripheral anionic site which concentrates the substrate towards the 
central site. Note that Aβ interacts with the peripheral site to trigger amyloid fibrillogenesis (Inestrosa et 
al., 1996). Choline resulting from ACh hydrolysis is then captured back to the presynaptic neuron where 
it is transformed into ACh by ChAT. Once released, ACh can bind onto two categories of cholinergic 
receptors: the G-protein coupled muscarinic receptors (mAChRs), divided in five subtypes (M1 to M5), 
and the pentameric ionotropic nicotinic receptors (nAChRs) constituted of α subunits (α2-10) and β 
subunits (β2-4). To sum up, several possible pharmacological means of enhancing cholinergic 
transmission are available. So far, investigation of AD therapies have focused primarily on the 
acetylcholinesterase inhibitors (AChEI), which increase the availability of brain ACh, and to a lesser 
extent on various compounds possessing agonistic effects on cholinergic receptors. 
2.2 The cholinergic hypothesis  
Formulated 35 years ago, the cholinergic hypothesis posits that cholinergic dysfunction contributes to 
cognitive deficits associated with aging and AD (Bartus et al., 1982). This hypothesis was based on three 
main streams of contemporary evidence emerging from both human and animal studies. First, 
cholinergic markers were affected in subjects with age-related cognitive decline. Second, alterations of 
the cholinergic system induced deficits similar to those of aged subjects and Alzheimer patients. Third, 
increasing central cholinergic activity had a beneficial effect on age-related cognitive deficits.  
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Hence, one of the most convincing evidence supporting the cholinergic hypothesis was provided by 
studies showing dramatic changes in the cholinergic system associated with cognitive decline. Strikingly, 
late stages of AD were accompanied by a severe loss of neurons from the NBM (Whitehouse et al., 
1981). In addition, a reduction of ChAT activity was reported as stronger and more reliable in AD brains 
compared to age-matched ones and it correlated to the degree of memory impairment (Bowen et al., 
1976; Davies and Maloney, 1976; Perry et al., 1978). This particular neurochemical change was thus 
considered highly specific to AD. Moderate cholinergic cell loss and reduction of cerebral ChAT activity 
associated with memory deficits were later confirmed in aged animals (Strong et al., 1980; Gilad et al., 
1987). Perturbations of other cholinergic markers such as muscarinic receptor binding were subtle but 
reliable in aged animals and elderly while quite inconsistent in AD patients (reviewed in Bartus et al. 
1982). It is important to note that, when the cholinergic hypothesis was formulated, there was no animal 
model of AD yet. Research on the cholinergic system and cognitive aging was limited to aged animals 
from species that do not develop spontaneously AD-like pathology. The idea of a specific role of the 
cholinergic system in cognitive aging was further supported by studies in humans showing that low doses 
of the muscarinic antagonist scopolamine induced cognitive deficits in young subjects resembling those 
of aged subject in tasks evaluating delayed recall of recent information (Drachman and Leavitt, 1974). 
This was also true in animals, from monkeys to rodents (Meyers and Domino 1964; Bartus 1979). As a 
logical correlate, several compounds stimulating the cholinergic system were thus considered in 
preclinical as well as clinical studies for their potential effects on memory impairments in normal and 
pathological aging. Most of them, such as ACh precursors (e.g., lecithin) or muscarinic agonists (e.g., 
arecoline), generally failed to improve performance in aged subjects and all of them led to disappointing 
clinical outcomes mainly due to poor pharmacokinetics and deleterious side effects. In fact, the best 
results came from anticholinesterase drugs, especially physostigmine which demonstrated facilitatory 
effects on cognitive performances in non-human primates (Bartus, 1979), young and old humans 
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(Drachman and Sahakian, 1980) and AD patients (Muramoto et al., 1979). The additional finding that 
deficits induced by scopolamine could be reliably relieved by physostigmine in rodent models made this 
compound the genuine ancestor of the cholinomimetics and opened a large avenue of preclinical and 
clinical research leading to the development of therapeutic drugs possessing anticholinesterase activity.  
Within less than 15 years after the publication of Bartus’ seminal paper (1982), marketing authorizations 
were given to the first of four cholinomimetics approved for the treatment of AD, namely tacrine 
(Cognex®, abandoned due to side effects) followed by donepezil (Aricept®), galantamine (Reminyl®) and 
rivastigmine (Exelon®). These compounds are mainly prescribed at the early stages of AD when cognitive 
symptoms are light to moderate. Benefits reported are modest and last less than two years (Courtney et 
al. 2004): cognitive performances increase or at least stabilize, and there is a global improvement in daily 
life activities. However, these effects are limited to a subpopulation of responders (30-40 % of the 
patients) impossible to identify a priori. It is noteworthy to remind that these drugs are the only ones 
approved as AD directed treatments up to now, aside the N-methyl-D-aspartate (NMDA) antagonist 
memantine. Although these treatments are not disease-modifying, these symptomatic drugs should 
certainly be acknowledged as useful for the daily life of patients within the limits evoked above. As long 
as the root causes of AD remains obscure, there is no pharmacological alternative at this time. It must be 
noted here that the widely used aged animal model may have misled research strategies to develop 
anticholinergic drugs based on several fundamental differences between healthy elderly and AD patients 
concerning the dramatic neuronal loss even at early stages (nearly absent in normal aging; see as 
example Small et al., 2004), the pattern of cortical vulnerability more centered on the medial temporal 
lobe and the nature of cholinergic basal forebrain alterations in AD (Grothe et al., 2010; Grothe et al., 
2012). 
2.3 The preclinical models of cognitive aging used for cholinomimetics development 
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As shown above, animal studies contributed to a great degree to the genesis of the cholinergic 
hypothesis in parallel to human studies. Thereafter, animal models were instrumental to the 
development of cholinomimetics. Similarities in the pattern of memory deficits induced by scopolamine 
compared to those found in AD prompted the use of animal models based on muscarinic receptor 
blockade for many years. These models have benefited from a long-standing experience in modulating 
memory performances through pharmacological manipulations with cholinergic drugs (Deutsch, 1971). 
The loss of cholinergic neurons in AD has also led to the development of models based on lesions of 
basal forebrain cholinergic nuclei using various approaches, first electrolytic, then excitotoxic and more 
recently immunotoxic (e.g., 192 IgG-saporin in rats). However, as the immunotoxic lesion technique was 
targeting more specifically the cholinergic neurons, results ended up disappointing in regard to the 
limited extent of memory deficits obtained in these models (Gallagher and Colombo, 1995; Parent and 
Baxter, 2004). As a matter of fact, the use of lesion models in developing cholinomimetics has been quite 
limited (Riekkinen, Riekkinen, et al., 1991; Mulder et al., 2005). This relative lack of effect on memory 
performance was totally unexpected and it seriously questioned the cholinergic hypothesis. Moreover, 
the strong impact of less specific lesions was subsequently interpreted as resulting from the loss of non-
cholinergic basal forebrain neurons (e.g., GABAergic, glutamatergic) which contributed evidently more to 
cognitive processing than initially thought (Parent and Baxter, 2004). However, it was later shown that 
specific cholinergic lesions did provoke massive spatial navigation impairments in both reference 
memory and working memory tasks when associated with mild neuronal loss within the temporal lobe 
(i.e., entorhinal cortex lesions; Traissard et al., 2007). This finding rehabilitated the concept of a critical 
role of cholinergic neuronal loss as a major aggravating factor for cognitive deficits when considered in 
the context of an already degenerating AD brain. In conclusion, preclinical behavioral studies that led to 
the successful development of cholinomimetic treatments were mainly restricted to pharmacological 
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(scopolamine) and lesion (NBM electrolytic and non-specific neurotoxin) models. Transgenic mouse 
model of AD, nowadays widely used for preclinical studies, was introduced later.  
As AD is primarily characterized by memory deficits, the animal models of cholinergic dysfunction were 
often tested for cognitive deficits on two main forms of memory affected in early AD: short term 
memory for events and spatial memory. Short-term memory was mostly evaluated using discrete trials 
characterized by particular trial-specific information to be recalled in various types of tasks taxing 
working memory, recognition memory or episodic-like memory (Bartus and Dean, 1988; Rupniak et al., 
1990; Dawson and Iversen, 1993; Luine et al., 2002; Prickaerts et al., 2005; Tronche et al., 2010). A 
particular attention was drawn to the rate of forgetting for recent event as immediate memory is 
typically not affected in aging and early AD, whereas delayed recall performance is expected to show 
accelerated decline. As for spatial navigation memory, it is usually tested in radial, Barnes or Morris 
water maze tasks (Hodges et al., 1990; Kwo-On-Yuen et al., 1990; Cheng et al., 1996), sometimes with an 
additional working memory component (Sweeney et al., 1988; Marighetto et al., 2008; but see 
Riekkinen, Aaltonen, et al., 1991). As evidently expected, both types of task are very sensitive to central 
cholinergic dysfunctions (Whishaw et al., 1985). Again, commonalties in the nature of memory 
impairments in early AD and healthy elderly, as well as in aged animals and models of AD, led to the use 
of aged animals to test the efficacy of cholinomimetic candidates (Bartus and Dean, 1988). Hence, 
although not in full agreement with the previously described task requirements, some of the most 
popular rodent memory tasks at that time, such as passive and active avoidance paradigms, were also 
used with some success in preclinical approaches mainly because testing parameters were set so that 
recent memory performance decayed rapidly. These tasks similarly highlighted a sensitivity of the 
memory performance to cholinergic modulation and aging in rodents (e.g., Flood et al., 1985). Finally, 
attentional paradigms were often included in the behavioral battery of tasks used to evaluate candidate 
drugs. Indeed, improvements of attention performance have been reported in AD patients treated with 
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cholinomimetics (e.g., Alhainen, Helkala, & Riekkinen, 1993). A similar enhancement of visuospatial 
attention by cholinergic drugs has been repeatedly shown in animal studies (Kirkby et al., 1996; Lindner 
et al., 2006), confirming a putative role of the basal forebrain cholinergic neurons in some forms of 
attentional functions critical to visuospatial tests (Robbins et al., 1989; Chiba et al., 1999). 
New animal models of AD were also created in light of the second major hypothesis of AD etiology. Ten 
years after the cholinergic hypothesis proposal and shortly before approval of the first AChEI, the 
amyloid cascade hypothesis indeed postulated that Aβ accumulation was the primary event in AD 
pathogenesis (Hardy and Higgins, 1992). This hypothesis has since drawn impressive effort in 
fundamental research as well as in the developments of drugs aimed at reducing Aβ accumulation. It 
prompted the emergence of models of AD based on intracerebral injection of Aβ, and other even more 
popular approaches that benefited from the transgenic mouse revolution. After several attempts based 
on APP knock-outs or normal human APP transgene, two mouse lines transgenic for APP FAD mutated 
genes finally developed the amyloid plaques which were the gold standard for an animal model at the 
time (Hsiao et al., 1995; Masliah et al., 1996). Since then, several other transgenic mouse and rat models 
have integrated human mutated tau and/or FAD mutations (Puzzo et al., 2014). Besides showing tau 
abnormalities, neuroinflammation and synaptic defects reminiscent from those found in AD, most of 
these models have displayed perturbations of the basal forebrain cholinergic system, although only very 
few models suffer from clear cholinergic neuronal loss (Cassel et al., 2008; Belarbi et al., 2011). The same 
is true for the temporal lobe in which only limited degeneration has been reported in these models. In 
general, the lack of massive AD-like neurodegeneration even at the oldest ages is one of the major limits 
that should be taken into account when interpreting preclinical approaches based on these models (Ashe 
and Zahs, 2010). The pattern of cognitive impairment is reminiscent of the one found in AD: most models 
show deficits in working memory, recognition memory, spatial navigation memory, and even in the 
newly developed episodic-like memory tasks (Webster et al., 2014). Surprisingly, no publication has yet 
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reported deficits in transgenic or other AD models in pattern separation tasks, despite their high 
sensitivity to cognitive decline in normal aging and early stages of AD in humans, and to cholinergic 
treatment in animals (Holden and Gilbert, 2012; Van Goethem et al., 2015). More importantly though, 
various AChEIs used in the primary AD models were successful in transgenic models (Dong et al., 2005), 
proving thereby the validity of these rodent models for the development of new cholinergic based 
therapies. 
Besides, animal models should also be employed to resolve open questions on AD which appear critical 
for the future development of cholinomimetic drugs. The first fundamental issue relates to the existence 
of responders and non-responders to AChEI treatments. The origin of these individual differences might 
depend on general factors like estrogens or the genotype (Craig et al., 2011). Such inter-individual 
variability in response to these treatments has been known for a long time in humans as well as in 
animals (Bartus, 1979; Davis et al., 1979), but the underlying mechanisms are unknown. Animal studies 
should certainly help to clarify this issue by exploring its potential physiological basis. It has been 
suggested that the efficacy of AChEIs could be related to the level of impairment or neurodegeneration 
of the subject as shown in aged rats (Stemmelin et al., 1998; Dumas and Newhouse, 2011). The work of 
Connelly et al (2005) tends to confirm this interpretation as AChEI non-responders show higher atrophy 
of the medial temporal lobe. Based on a morphometric indicator, the extent of cholinergic degeneration 
of the NBM has been inversely correlated with the magnitude of response to treatment with AChEI in AD 
patients (Tanaka et al., 2003). These results suggest that AChEI responders benefit from the prolonged 
availability of ACh because cholinergic innervation within target structures decreases as basal forebrain 
atrophy progresses. Also, the genetic risk factor APOE4 has been associated with both reduced 
hippocampal cholinergic markers and unresponsiveness to AChEI in AD patients (Farlow et al., 1996; but 
see Waring et al., 2015). Recently, we highlighted a potential mechanism by which APOE4 could disrupt 
AChEI response. By mimicking the earliest stage of AD with a partial entorhinal cortex lesion in mice, we 
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have shown the extraordinary ability of the mammalian brain to normalize lesion-induced spatial 
memory deficit and hippocampal neuronal hyper-activity through the compensatory hippocampal 
cholinergic sprouting in response to entorhinal cell loss (Bott et al., in press). This cholinergic sprouting 
transiently increased the territory of septo-hippocampal cholinergic innervation in the whole 
hippocampus before glutamatergic reinnervation occurred and seemed to take over for functional 
recovery. Interestingly, the cholinergic sprouting was abolished in mice expressing the human APOE4 
allele, but not in those expressing the APOE3 allele, which may explain several negative effects of APOE4 
such as marked hippocampal hyperactivity (Filippini et al., 2009) and reduced responsiveness to AChEI in 
AD patients (Farlow et al., 1996). Moreover, it is noteworthy that reactive cholinergic sprouting and 
glutamatergic reinnervation do exist within the hippocampus in response to entorhinal cortex pathology 
in early stages of the disease (Geddes et al., 1985; Ikonomovic et al., 2003). Another study in monkeys 
has recently shown that cholinergic innervation within the temporal lobe cortex facilitates functional 
recovery after structural lesions impairing episodic memory performances (Croxson et al., 2012). Taken 
together, these animal studies confirm that the cholinergic system plays an important role in brain 
compensatory mechanisms relevant to AD. These are worth being further explored experimentally with 
the aim of developing interventions favoring or mimicking natural defenses of the brain against the 
disease. Another example of cholinomimetic-relevant issue that should benefit from investigations in 
animals is the characterization of pharmacological activities, apart from AChE inhibition, of some clinical 
drugs which could play a role in their beneficial effects in AD (Wilkinson et al., 2004). For example, 
inhibition of BuChE (Cheng et al., 1996) as well as the stimulating effect on nicotinic receptors density or 
NMDA receptor activity in key structures for memory may contribute to these effects (Barnes et al., 
2000). Altogether, these examples demonstrate how critical animal studies can be in the future to 
improve our understanding of the mechanisms involved in AChEI responsiveness and to characterize 
more precisely the role of the basal forebrain cholinergic neurons in the earliest stages of AD. 
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3. Renewed interest for the cholinergic system in the development of 
Alzheimer’s disease  
It is obvious these days that the ACh deficit associated to the degeneration of the cholinergic basal 
forebrain neurons cannot be the single cause of AD as proposed initially in the cholinergic hypothesis. 
This is mainly because treatments increasing the cholinergic drive do not halt the pathological process 
(Raschetti et al., 2007; Schneider et al., 2014) and other cerebral structures involved in memory, such as 
the entorhinal cortex, were found to degenerate at least as early as the basal forebrain (Kordower et al., 
2001). In the meantime, the major AD features, namely soluble forms of Aβ and tau, have been put 
forward as responsible for the development of the disease. ACh-related deficits were progressively 
relegated to a mere consequence of these proteomic-related events. However, despite considerable 
research effort, evidence for Aβ- and/or tau-related abnormalities as being the cause of AD still remains 
inconclusive as corresponding treatments have failed so far. Due to this dramatic difficulty to identify the 
causes of AD, the cholinergic hypothesis is now going through a renewal period inscribed within the 
concept of AD being a more complex and multifactorial disease in which cholinergic deficits represent 
only one aspect of the pathogenesis. For example, a recent view postulates that AD is primarily a 
hippocampal dementia resulting from a combination of factors not necessarily identical in all patients 
(Craig et al., 2011). In this context, cholinergic depletion, already present in the elderly, is seen as a risk 
factor of AD interacting with other risk factors like stress or injury. As the occurrence of such 
circumstances becomes more frequent with age, an increasingly large combination of them would 
ultimately disrupt cognitive and structural compensatory mechanisms which are normally engaged to 
cope with brain dysfunctions and damages. This would favor the conversion to AD. 
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Cholinergic deficits, not the sole cause of AD anymore, could nonetheless heavily contribute to the 
disease progression. Recent findings indicate that atrophy of the cholinergic basal forebrain begins 
during normal aging and is aggravated in patients with mild cognitive impairment (MCI, a prodromal 
stage of AD) (Grothe et al., 2012). It thus appears at an earlier stage than initially thought and progresses 
in parallel to cortical atrophy (Kilimann et al., 2016). Indeed, early atrophies of both the NBM and of 
cortical structures of the temporal lobe were shown to be associated with impaired delayed recall in MCI 
patients (Grothe et al., 2010). Reduction in basal forebrain volume also contributes to spatial navigation 
deficits in AD patients (Kerbler et al., 2015). Interestingly, hippocampal atrophy in amnestic MCI patients 
(i.e., likely to become AD) was slowed down by a one-year donepezil treatment (Dubois et al., 2015). 
Note however that no cognitive improvement ensued, similarly to clinical trials testing the preventive 
effects of AChEIs on MCI patients’ cognition (Schneider et al., 2014). This highlights that early cholinergic 
deficits cannot entirely elucidate the AD pathogenesis. Long-term cholinergic depletion has nonetheless 
recently been shown to alter gene expression of some transcripts related to the AD pathology in the 
hippocampus of aged mice with a knockout of hippocampal vesicular acetylcholine transporter (Kolisnyk 
et al., 2016). These mice displayed age-related changes in APP processing, tau hyperphosphorylation, 
hippocampal neuronal loss and synaptic abnormalities, as well as cognitive deficits.  
Thus, early cholinergic deficits appear to have long-term consequences on the integrity of innervated 
systems. This could be explained by the neuroprotective action of the cholinergic system against several 
AD neuropathological events such as neuro-inflammation, Aβ accumulation and abnormal tau 
phosphorylation (Ovsepian et al., 2015; Echeverria et al., 2016). For instance, cholinergic receptors 
possess a high affinity for Aβ or tau protein whose binding induce some intracellular mechanisms 
controlling further production of these ligands (Ovsepian et al., 2015). M1 receptors activation promotes 
non-amyloidogenic cleavage of APP via the modulation of major APP-cleaving proteases (Davis et al., 
2010). Tau phosphorylation is also regulated by cholinergic receptors, decreased and increased by 
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mAChRs and nAChRs activation respectively (Caccamo et al., 2006; Buckingham et al., 2009). Basal 
forebrain cholinergic terminals expressing p75 neurotrophic receptors would also play a special role in 
clearing Aβ via its degradation after endocytosis (Ovsepian et al., 2015).  
In addition to this neuroprotective action, there are several indications that the cholinergic system 
undergoes adaptive changes in cognitively important target structures like the hippocampus, as 
previously evoked (Bott et al., in press; Mufson et al., 2016), or the frontal cortex (DeKosky et al., 2002; 
Ikonomovic et al., 2003). In human studies, these changes were mainly represented by increased ChAT 
activity, which was interpreted as resulting from a transient compensatory sprouting by the remaining 
cholinergic terminals in the hippocampus following entorhinal disconnection, and more probably an up-
regulation of the enzymatic activity in the frontal cortex (Mufson et al., 2016). Another example of 
cholinergic activity adaptability can be found in the rapidly increased production of an AChE variant 
following low levels of Aβ (Li et al., 2013). This variant is more frequent under stress conditions, helping 
neuroprotection, neural development and possibly ACh release. Besides, ACh itself can favor various 
forms of compensatory neuronal plasticity outside the sprouting described above: for example, dendritic 
branching (Mufson et al., 2016), neurogenesis (Kotani et al., 2006) and synaptic plasticity (e.g., 
Rasmusson, 2000). At a more functional level, the cholinergic system appears to be involved in the 
capacity of the brain to shift on alternative neuronal networks to offset the fornix degeneration and 
maintain visual recall memory performances (Ray et al., 2015). Indeed ACh is known to promote 
attention, memory and cognitive flexibility by supporting the compensatory engagement of frontal 
regions following AD-related degeneration of more posterior structures (Dumas and Newhouse, 2011; 
Hasselmo and Sarter, 2011). Moreover, increased reorganization of glutamatergic terminals has been 
shown in regions similar to those sustaining cholinergic plasticity, and in MCI more than in AD (Mufson et 
al., 2016). This may explain why AChEI/memantine combined therapies have some beneficial effects 
(Dantoine et al., 2006). In any case, there is clearly a need to better understand mechanisms and factors 
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involved in cholinergic and glutamatergic reactive neuroplasticity as they may efficiently delay a critical 
shift to heavier cognitive impairments associated with a serious degradation of the quality of life of the 
patients and their entourage. Better knowing the delicate equilibrium preserving cognitive performance 
and developing means to prolong this “compensated” state would open a larger time-window for 
symptomatic and possibly disease-modifying therapies.  
 
4. The future of cholinergic drugs 
 
Establishing the time line of the various subtle cholinergic dysfunctions should further suggest more 
specific therapies than the AChEIs used so far, possibly adapted to each stage of the disease. It is thus 
not surprising that, despite the modest (but consistent; Schneider et al., 2014) symptomatic benefits of 
AChEIs and the rise of alternative hypotheses about AD pathogenesis and etiology, cholinergic therapies 
are still relevant and actively researched. Presenting the numerous new cholinergic and non-cholinergic 
molecules currently tested in vivo, in vitro or even in silico is beyond the scope of this review. The 
following sections aim only at providing a brief perspective on the main cholinergic AD therapies in 
preparation, starting with the AChEI drug category. 
 
4.1. Future of AChEIs 
The most straightforward option for treating AD is to improve the AChEIs. Many compounds with more 
potent AChEI properties are currently being developed, either extracted from natural products (e.g., 
coumarins, flavonoid derivatives) or computationally designed (Anand et al., 2014; Kumar et al., 2016). 
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Research for newer drugs in AD therapy is however a complex process in which it is certainly difficult to 
take the multitude of factors involved in the disease. In terms of the AChEI action, at least four aspects 
should be considered. 
First, the inhibition of the AChE could be more efficient by blocking both the catalytic and the peripheral 
sites of AChE. Except donepezil, the AChEI drugs used in therapies bind only to the catalytic site (Ismaili 
et al., 2016). This pharmacological aspect has been explored actively for the last decade and more recent 
molecules like donepezil-tacrine hybrids, coumarins and huperzine A often act as dual binding site 
inhibitors (Ismaili et al., 2016; Kumar et al., 2016). Interestingly, positive activity of the peripheral anionic 
site on the prevention of Aβ aggregation should be taken into consideration in the development of new 
AChEIs (Inestrosa et al., 1996).  
Second, various forms of cholinesterase enzymes exist, with different locations and functions 
(Zimmermann, 2013). For example, AChE and BuChE differ mostly by their location and their affinity for 
ACh (Unzeta et al., 2016) but BuChE might compensate for the loss of AChE in AD (Greig et al., 2005). In 
severe cases of the disease, AChE expression is indeed decreased while that of BuChE is increased (Reid 
et al., 2013). Although no differences in clinical outcomes have yet been observed between AChE-
selective (e.g., donepezil) and less selective drugs (e.g., rivastigmine inhibits both AChE and BuChE; 
Hogan, 2014), developing drugs inhibiting both enzymes might thus prove useful (Zimmermann, 2013). 
Overall, the existence of various forms of cholinesterase enzymes should be considered in the design of 
more efficient drugs. 
Third, the spatial selectivity of AChEI action should be better controlled. The systemic administration of 
the current AChEIs makes it difficult to target their action to the brain and, more importantly, to areas 
affected by cholinergic depletion. One of the main risks is to trigger excessive upregulation of the 
cholinergic tone in relatively preserved areas like the striatum. This could have potentially undesirable 
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consequences such as basal ganglia-related motor disorders that are rarely induced by AChEIs alone but 
may occur more frequently when combined with antipsychotic drugs in some AD prescriptions (Shimizu 
et al., 2015). In order to boost their spatial efficacy, AChEI treatment could be combined with a localized 
electrical stimulation of the NBM neurons (Gratwicke et al., 2013). Such therapeutic tool could also 
ultimately answer to another issue of AChEI drugs: their temporal dynamics. 
Indeed, a fourth area of improvement relates to the poor temporal resolution of AChEI treatment. The 
fundamental mechanism of action of these drugs consists in extending the availability of released ACh 
over longer periods than normal. On top of maybe transiently reducing the probability of further ACh 
release due to a higher likelihood of presynaptic autoreceptors activation, this could mask incoming 
phasic cholinergic signal onto postsynaptic neurons (Dumas and Newhouse, 2011; Hasselmo and Sarter, 
2011). This is especially important because ACh function would differ depending on the time scale of its 
release, phasic or tonic (Hasselmo and Sarter, 2011). Indeed, these two modes of ACh release are each 
known to contribute in a specific way to learning and memory processes. As suggested above, brain 
stimulation could help mastering temporal dynamics of ACh availability but the step to the clinical trials 
is far from now. It is noteworthy that such considerations on cholinergic dynamics appear more adapted 
for symptomatic therapies but of limited interest for disease modifying therapies.  
The above considerations suggest ways of improving AChEI drugs, with some being already actively 
explored. The most notable development in the domain of AChEI drugs is nonetheless the combination 
of their AChEI action with other beneficial effects from non-cholinergic drugs (e.g., anti-amyloid, 
antioxidant, anti-inflammatory). Given the multifactorial nature of the AD pathology, the concurrent use 
of an AChEI and another drug has already showed interesting results. Indeed, memantine, a drug 
targeting primarily NMDA receptors, is now sometimes successfully administered alongside an AChEI 
drug (Dantoine et al., 2006). More recently it has been shown that the serotoninergic antagonist 
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idalopirdine can potentiate the pro-cognitive effect of donepezil in moderate AD patients (Wilkinson et 
al., 2014). Several preclinical investigations also explored the benefits of various combinations of existing 
therapeutics in mouse models of AD (Jacobsen et al., 2014; Chumakov et al., 2015). Nowadays, drug 
combination is taken further by creating single molecules possessing the effects of several drugs acting 
simultaneously on different targets. This should lead to a lower risk of drug interactions, an easier 
control of the pharmacokinetics and an easier treatment compliance given a simpler drug schedule. 
Unsurprisingly, several of such ‘multi-target directed ligands’ are based on classic AChEI molecules like 
donepezil (Agis-Torres et al., 2014; Ismaili et al., 2016; Unzeta et al., 2016). For example, donecopride is 
a promising AChEI-serotoninergic antagonist hybrid molecule that can counteract scopolamine-induced 
amnesia in a working memory task (Rochais et al., 2015) and enhance object recognition memory 
(Lecoutey et al., 2014) in mice.  
In conclusion, as the main option for AD treatment, drugs offering an AChEI action are still actively 
developed. However, increasing their potency is not simply a question of improving the level and 
duration of ACh availability. On top of combining complementary neuroprotective influences, either 
intrinsic to AChE or by combining compounds acting on different systems, future AChEI drugs should 
ideally display an adequate targeting of the cholinesterase enzymes hopefully alongside a refined spatio-
temporal dynamics.  
 
4.2. An old alternative: targeting cholinergic receptors  
Alternatively to reducing the degradation rate of ACh, the activity elicited by the cholinergic system can 
be modulated via its target receptors. The nicotinic cholinergic receptors (nAChRs) are ionotropic 
receptors displaying a fast activation time adapted for mediating phasic release-associated cholinergic 
functions. As muscarinic cholinergic receptors (mAChRs; five subtypes: M1-5) are metabotropic, being 
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coupled with a G protein, they show a slower action but also longer-lasting, which is maybe more 
adapted to cholinergic functions mediated through tonic release.  
Muscarinic receptors 
M1 receptors are the most promising cholinergic targets for AD (Foster et al., 2014). M2, M3 and M4 
receptors should not be targeted to avoid psychotic or peripheral side effects (Bymaster et al., 2003; 
Foster et al., 2014). M1 receptors are involved in cognition and underlying mechanisms (e.g., 
Anagnostaras et al., 2003; Dennis et al., 2016). Highly selective M1 agonists have been available only 
recently and their efficacy is still being assessed. Overall, they induce pro-cognitive effects in rodents 
(Ma et al., 2009; Lebois et al., 2010; Digby et al., 2012; Melancon et al., 2013), AD-model mice (Shirey et 
al., 2009) or humans (Nathan et al., 2013; Schneider et al., 2014). As M1 receptor density is also 
relatively preserved in AD (Mulugeta et al., 2003), drugs activating M1 receptors are overall less 
dependent on the current state of cholinergic neurodegeneration. It could be hypothesized that direct 
agonists, by binding to the same site than ACh (i.e., orthosteric site), could be more helpful late in the 
pathology when ACh is in short supply (Jiang et al., 2014). Alternatively, positive allosteric modulators 
offer several advantages thanks to their binding to a different site (i.e., allosteric) of M1 receptors than 
ACh (Melancon et al., 2013; Foster et al., 2014). First, at earlier stages of AD, these molecules might be 
better suited because instead of replacing ACh, they will potentiate the effect of its natural release (Jiang 
et al., 2014; Kruse et al., 2014). Second, these drugs would also respect the dynamics of the cholinergic 
signaling, which partly answers to above considerations for improving the temporal selectivity of the 
AChEIs. In addition to their symptomatic action, M1 receptor agonists are very promising because they 
have a neuroprotective, disease-modifying potential by reducing tau phosphorylation and production of 
Aβ (e.g., Beach et al., 2001; Caccamo et al., 2006). As Aβ can disrupt the M1 receptor function, M1-
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mediated reduction of Aβ levels may initiate an interesting beneficial positive feedback loop (Fisher, 
2012). 
Nicotinic receptors   
Along the development of AD, the cortical and hippocampal expression of several types of nAChRs is 
reduced (Guan et al., 2000; Sabbagh et al., 2006). Among those, α7 receptors are of particular interest 
because they participate in attentional and mnesic functions, as well as in synaptic plasticity (Fisher, 
2012; Lombardo and Maskos, 2015; Echeverria et al., 2016). Furthermore, neurons expressing these 
receptors are especially vulnerable to AD (D’Andrea and Nagele, 2006) presumably via a “switch 
position” depending on Aβ levels (Buckingham et al., 2009; Ovsepian et al., 2015; Echeverria et al., 2016). 
At low dose, Aβ would activate α7 receptors and trigger neuroprotective intracellular mechanisms, while 
a higher concentration would prompt alternative intracellular pathways leading to neurotoxicity. Unlike 
M1 receptors though, α7 receptors might not protect against, but actually enhance, tau phosphorylation 
(Fisher, 2012). Therefore, despite some pro-cognitive effects observed in animals and humans (Hilt et al., 
2009; Echeverria et al., 2011), the net effect of both beneficial and detrimental actions of α7 agonists is 
unclear (Anand et al., 2014). Several molecules are currently under test but α7 receptor-based therapies 
might yield less promising results than their M1 counterparts. In general, it must be recognized that 
recent clinical trials with cholinergic compounds have been disappointing at the level of efficiency on 
cognitive symptoms as well as undesirable side effects (Lewis et al., 2017; McArthur et al., 2010). This 
certainly emphasizes that we need a better understanding of the translational gap for therapeutics 
targeting nicotinic and muscarinic receptors. 
 
5. As a conclusion, specific progresses are needed on early stages of AD 
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A convincing and exhaustive story of the etiology of AD has not been reached yet, supporting a 
multifactorial view of this disease. Cholinergic cells loss was first relegated to a late-phase consequence 
of the condition, whereas current research has revealed a multitude of plastic changes taking place much 
before the first overt cognitive symptoms. Clearly, several of these changes are of a cholinergic nature 
and seem to underlie compensatory mechanisms that efficiently delay conversion to AD. Unfortunately, 
advancing degeneration of the cholinergic basal forebrain progressively dismantles the compensatory 
mechanisms, mainly in the hippocampus and the cortex. Based on research in MCI and AD patients, it is 
however difficult to unravel the diversity and the exact role of cholinergic changes engaged in the 
maintenance of cognitive functions given the concomitance of amyloid and tau pathologies and their 
complex mutual interactions. Animal studies will certainly offer some valuable insight on this issue using, 
this time as a clear advantage, the large diversity of rodent models mimicking only limited aspects of 
early phases of this complex disease (Ashe and Zahs, 2010). Besides the study of cholinergic responses to 
the disease, there is also a crucial need to uncover the timeline and the nature of the ‘precocious’ 
deficits of the cholinergic system during normal aging (e.g., Schliebs and Arendt, 2011) as it is undeniably 
implicated in some aspects of AD etiology (disease superimposed on cholinergic decline) and the 
progression of the disease. In this regard, it would also be of great interest to study the cholinergic 
system in light of concepts such as brain resilience and cognitive reserve (e.g., Stern, 2012) focusing on 
factors leading to constitutively higher neuronal and/or synaptic density or increased ability to recruit 
alternative brain circuits. Both properties should alleviate the cognitive symptoms in AD and delay the 
conversion of MCI to AD (Mufson et al., 2016). Studies in rodents raised in enriched environments have 
already provided some interesting data showing a preventive effect of life enrichment on the cholinergic 
basal forebrain (Harati et al., 2013). Finally, characterizations of early clinical subgroups should be 
associated with the development of corresponding biological and cognitive biomarkers of easy use in 
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clinical settings. Tremendous technical progress has been made in this domain during the last few years 
regarding the detection of Aβ or cholinergic nuclei atrophy levels via structural imagery in humans, but 
non-invasive markers of the cholinergic activity, possibly more important than purely structural markers, 
are lacking. The battery of cognitive tasks used to categorize the patients as NCI, MCI or AD could be 
refined by the inclusion of new paradigms like pattern separation tasks (Stark et al., 2013). Functional 
markers of the cholinergic state could be further highlighted when combining these tasks with functional 
imagery techniques. Electroencephalography, especially, holds some interesting potential by allowing 
detection of frontal and hippocampal theta oscillations abnormalities during early phases of cognitive 
decline (Hamm et al., 2015).  
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